Cyclacel Pharmaceuticals CYCCP
$ 6.05
0.0%
Facebook
Twitter
ВКонтакте
Telegram
Сообщить о неточностиКвартальный отчет 2024-Q3
добавлен 12.11.2024
Cyclacel Pharmaceuticals Мультипликаторы 2011-2024 | CYCCP
Мультипликаторы по годам Cyclacel Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.8 | -0.5 | -3.3 | - | - | - | - | - | - | - | - | - | - |
P/S |
43.8 | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
- | - | -2.1 | -3.4 | -0.5 | -0.6 | -1.9 | -3.5 | -0.5 | -0.9 | -1.3 | -1.7 | -0.3 |
EV (Enterprise Value) |
23.2 млн | -678 тыс. | 30.2 млн | -29.9 млн | -8.27 млн | -13 млн | -19.7 млн | -11.1 млн | -14.5 млн | -16.5 млн | -23.6 млн | -7.08 млн | -18 млн |
EBITDA per Share |
-24 | -44 | -2.56 | - | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
-1.0 | 3.1 | 1.2 | 1.8 | 2.5 | 1.2 | 1.3 | 1.1 | 1.7 | 1.1 | 1.5 | ||
PEG |
- | - | - | - | - | - | - | - | - | - | - | ||
P/B |
30.3 | 0.5 | 1.6 | - | - | - | - | - | - | - | - | - | - |
P/CF |
-1.1 | -0.5 | -3.3 | - | - | - | - | - | - | - | - | - | - |
ROE % |
-3715.82 | -132.99 | -50.69 | -25.39 | -66.94 | -47.72 | -34.32 | -82.61 | -76.15 | -89.39 | -36.23 | -131.61 | -78.17 |
ROA % |
-256.16 | -75.57 | -44.35 | -22.95 | -51.15 | -36.77 | -28.73 | -59.97 | -57.91 | -65.97 | -28.58 | -68.13 | -58.63 |
ROCE % |
-4193.25 | -173.51 | -61.56 | -30.99 | -75.12 | -62.11 | -43.36 | -98.24 | -85.06 | -102.48 | -64.14 | -150.74 | -84.04 |
Current Ratio |
1.1 | 3.7 | 8.0 | 14.3 | 5.8 | 4.4 | 6.3 | 3.7 | 4.3 | 3.9 | 4.7 | 2.0 | 4.0 |
DSO |
- | - | - | - | - | 3659.7 | - | 890.6 | 568.2 | 728.3 | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | 184.5 |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | 1787.5 |
Операционный цикл |
- | - | - | - | - | - | - | - | - | - | - | - | 184.5 |
Финансовый цикл |
- | - | - | - | - | - | - | - | - | - | - | - | -1603.0 |
Все данные представлены в валюте USD
Мультипликаторы поквартально Cyclacel Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | - | - | -0.44 | -0.47 | - | -0.42 | -0.46 | -0.42 | - | -0.54 | -0.56 | -0.5 | - | -0.47 | -0.58 | -1.48 | - | -2.27 | -2.13 | -2.77 | - | -0.18 | -0.16 | -0.12 | - | -0.91 | -0.5 | -0.38 | - | -0.86 | -1.01 | -1.04 | - | -0.95 | -1.19 | -0.19 | - | -0.22 | -0.22 | -0.25 | - | -0.32 | 0.1 | -1.18 | - | -0.25 | -0.45 | -0.4 | - | -0.07 | -0.08 | -0.1 |
EBITDA per Share |
- | - | -3.3 | - | - | -0.58 | - | -0.52 | -0.57 | -0.66 | - | -0.64 | -0.66 | -0.61 | - | -0.53 | -0.64 | -2.81 | - | -2.71 | -2.71 | -3.22 | - | -0.2 | -0.2 | -0.18 | - | -0.21 | -0.56 | -0.63 | - | -0.97 | -1.23 | -1.25 | - | -1.12 | -1.23 | -0.2 | - | -0.24 | -0.24 | -0.28 | - | -0.32 | -0.3 | -0.41 | - | -0.41 | -0.45 | -0.4 | - | -0.47 | -0.08 | -0.1 |
ROE % |
-96.80 | -404.63 | -135.80 | -186.36 | -209.45 | -118.53 | -50.53 | -62.59 | -51.55 | -48.27 | -31.16 | -37.94 | -32.67 | -27.32 | -16.96 | -33.22 | -42.68 | -51.42 | -47.24 | -60.78 | -58.07 | -54.96 | -34.50 | -43.03 | -38.02 | -35.94 | -25.72 | -46.36 | -58.47 | -69.20 | -62.72 | -77.10 | -70.85 | -67.84 | -58.23 | -80.86 | -89.10 | -93.52 | -67.26 | -85.12 | -80.35 | -52.84 | -23.53 | -42.39 | -43.40 | -84.43 | -84.06 | -101.73 | -100.53 | -83.04 | -59.41 | -17.67 | -18.22 | -23.53 |
ROA % |
-157.06 | -153.82 | -140.37 | -75.87 | -92.30 | -72.11 | -39.74 | -50.82 | -45.47 | -43.60 | -28.86 | -34.99 | -30.04 | -24.86 | -15.33 | -27.75 | -34.04 | -39.80 | -36.10 | -46.53 | -44.55 | -42.25 | -26.58 | -33.72 | -30.43 | -29.49 | -21.53 | -36.52 | -44.36 | -51.03 | -45.53 | -56.47 | -52.42 | -50.86 | -44.29 | -60.99 | -66.75 | -69.61 | -49.64 | -63.73 | -61.12 | -40.54 | -18.56 | -28.33 | -24.01 | -46.69 | -43.52 | -56.77 | -60.25 | -55.43 | -44.56 | -13.25 | -13.66 | -17.65 |
ROCE % |
-58.36 | -398.23 | -105.59 | -216.87 | -246.18 | -149.89 | -68.09 | -82.59 | -67.78 | -62.75 | -37.57 | -45.31 | -38.54 | -31.86 | -22.45 | -42.53 | -54.87 | -67.41 | -58.90 | -74.97 | -70.97 | -67.13 | -46.37 | -56.08 | -49.70 | -45.00 | -33.51 | -57.87 | -72.53 | -87.44 | -76.94 | -94.96 | -88.61 | -81.47 | -65.35 | -91.50 | -99.62 | -106.12 | -76.79 | -97.47 | -92.01 | -81.13 | -49.96 | -85.11 | -99.59 | -122.81 | -104.29 | -124.19 | -108.93 | -90.36 | -63.98 | -19.90 | -19.47 | -24.62 |
Current Ratio |
0.8 | 1.1 | 0.7 | 1.1 | 2.4 | 3.0 | 3.7 | 7.0 | 6.9 | 6.4 | 8.0 | 12.4 | 14.9 | 13.8 | 10.4 | 10.4 | 10.4 | 10.4 | 4.2 | 4.2 | 4.2 | 4.2 | 4.4 | 4.4 | 4.4 | 4.4 | 6.1 | 6.1 | 6.1 | 6.1 | 3.6 | 3.6 | 3.6 | 3.6 | 4.2 | 4.2 | 4.2 | 4.2 | 3.8 | 3.8 | 3.8 | 3.8 | 4.7 | 4.7 | 4.7 | 4.7 | 2.1 | 2.1 | 2.1 | 2.1 | 4.0 | 4.0 | 4.0 | 4.0 |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.0 | 79.0 | 32.9 | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Операционный цикл |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.0 | 79.0 | 32.9 | - | - | - | - |
Финансовый цикл |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.0 | 79.0 | 32.9 | - | - | - | - |
Все данные представлены в валюте USD